Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006013 · ClinicalTrials.gov registry record · Phase 2
SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 4
- Study locations
NCT00006013: Completed Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Fox Chase Cancer Center.
NCT00006013 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 21 participants, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006013, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 4
- Study locations
Study Summary
RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
Conditions Studied
Interventions
- DRUG semaxanib
Study Locations (4)
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Illinois
- University of Chicago Cancer Research Center - Chicago
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2000-06 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
What the finished NCT00006013 record still lists
NCT00006013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 769-participant average among 26 other Multiple Myeloma and Plasma Cell Neoplasm trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which semaxanib is the first listed.
NCT00006013 reports a single indexed study location in Florida, Illinois, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00006013 about?
NCT00006013 is a clinical study titled "SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma". RATIONALE: SU5416 may stop the growth of multiple myeloma by stopping blood flow to the cancer cells. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have refractory or relapsed multiple myeloma.
What is the current status of trial NCT00006013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2000-06. Estimated completion is 2003-01.
What conditions does trial NCT00006013 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00006013?
The interventions under investigation include: semaxanib (DRUG).
Who is sponsoring clinical trial NCT00006013?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006013 being conducted?
This trial has 4 study locations across Florida, Illinois, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00006013's enrollment target sits among peer trials
21 22nd of 26 higher than 5 of 26 other Multiple Myeloma and Plasma Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma and Plasma Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
COMPLETED · Phase 2
-
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia